NASDAQ: INDPIndaptus Therapeutics Inc Stock
$2.18-0.17 (-7.23%)
Updated Apr 25, 2024
INDP Price
$2.18
Fair Value Price
$1.57
Market Cap
$18.61M
52 Week Low
$1.56
52 Week High
$4.08
P/E
-1.19x
P/B
1.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.42M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
-$13M
Beta
1.15
Next Earnings
May 3, 2024
Ex-Dividend
N/A
Next Dividend
N/A
INDP Overview
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INDP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INDP ($2.18) is overvalued by 38.88% relative to our estimate of its Fair Value price of $1.57 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INDP ($2.18) is not significantly undervalued (38.88%) relative to our estimate of its Fair Value price of $1.57 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INDP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INDP due diligence checks available for Premium users.
Be the first to know about important INDP news, forecast changes, insider trades & much more!
INDP News
Valuation
INDP fair value
Fair Value of INDP stock based on Discounted Cash Flow (DCF)
Price
$2.18
Fair Value
$1.57
Overvalued by
38.88%
INDP ($2.18) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INDP ($2.18) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INDP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INDP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.19x
Industry
15.41x
Market
40.97x
INDP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.54x
Industry
5.8x
INDP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INDP's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.0M
Profit Margin
0%
INDP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$14.9M
Liabilities
$2.8M
Debt to equity
0.24
INDP's short-term assets ($14.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INDP's short-term assets ($14.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INDP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
INDP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.6M
Investing
$0.0
Financing
$0.0
INDP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INDP vs Biotech Stocks
Indaptus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.